Publication

Comparative Analysis of In Vitro processivity of HIV-1 Reverse Transcriptases Containing Mutations 65R, 74V, 184V and 65R+74V

Downloadable Content

Persistent URL
Last modified
  • 02/20/2025
Type of Material
Authors
    Prem L Sharma, Emory UniversityJames H Nettles, Emory UniversityAnya Feldman, Emory UniversityKimberly Rapp, Emory UniversityRaymond F Schinazi, Emory University
Language
  • English
Date
  • 2009-09
Publisher
  • Elsevier Masson
Publication Version
Copyright Statement
  • Published by Elsevier B.V.
License
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 0166-3542
Volume
  • 83
Issue
  • 3
Start Page
  • 317
End Page
  • 323
Grant/Funding Information
  • This work was supported in part by NIH grant RO-1-AI-47726 (PLS) and VA MERIT Award (PLS), 2P30-AI-50409 (CFAR grant to RFS), 5R37-AI-041980 (RFS) and the US Department of Veterans Affairs.
Abstract
  • While HIV-1 reverse transcriptase (RT) mutations of M to V at position 184 are commonly observed in the clinic, the double mutation of 65R+74V is rarely seen. It has been demonstrated that rapid R→K reversion occurs at RT codon 65 during replication of HIV-1 in human peripheral blood mononuclear cells containing 65R+74V mutations and that processivity of the RT is reduced relative to wild type. However, clinical studies show that M184V can be detected after several months of therapy interruption, suggesting more effective processivity. Herein, the in vitro RT processivity of genetically engineered M184V and double mutant 65R+74V was compared. Virion-associated RTs of WT pNL4-3, K65R, L74V, M184V and 65R+74V were used to perform RT processivity assays in the presence of trap, poly(rC)-oligo(dG). Both RTs with 184V and 65R+74V mutations exhibited similar processivity when compared with each other and a significantly decreased processivity as compared to WT RT. Both mutant RTs synthesized shorter cDNA molecules (37–42 nt) relative to WT RT, which made longer (65–70 nt) cDNA molecules. Since these surprising biochemical results cannot explain the clinical phenotype, a hypothesis is presented to explain the discrepancy and suggest new approaches for future testing.
Author Notes
  • Correspondence: Dr. Prem L. Sharma, Department of Microbiology and Immunology, Emory University School of Medicine and Department of Veterans Affairs, 1670 Clairmont Road, Medical Research 151MV, Decatur, GA 30033, USA; Tel: +1-404-321-6111 ext. 7495; FAX: +1-404-728-7780; E-mail: plsharm@emory.edu
Keywords
Research Categories
  • Health Sciences, Immunology

Tools

Relations

In Collection:

Items